The company’s data package includes three Proffered Paper presentations and three Rapid Oral sessions, covering more than ten distinct oncology areas. Key highlights include phase 3 results for its HER2-targeted trastuzumab rezetecan in advanced breast cancer and interim data for the HER3-targeted ruzaltatug rezetecan in EGFR-mutated non-small-cell lung cancer. Both candidates represent the core of the firm's expanding ADC development platform.
Beyond these targets, Hengrui is addressing difficult-to-treat cancers through its KRAS G12D inhibitor, HRS-4642. Preliminary phase 2 results for a combination regimen involving this inhibitor will be featured as a Rapid Oral presentation, signaling a strategic push into targeted therapies for specific genetic mutations. The company will also host an exhibition booth for the second year, facilitating international scientific exchange as it transitions its R&D focus toward global clinical applications.
Comments (0)
No comments yet. Be the first!